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Abstract Cervical intraepithelial neoplasia (CIN) represents a spectrum of epithelial changes that 
provide an excellent model for developing chemopreventive interventions for cervical cancer. Possible 
drug effect surrogate endpoint biomarkers are dependent on the agent under investigation. Published 
and preliminary clinical reports suggest retinoids and carotenoids are effective chemopreventive agents 
for CIN. Determination of plasma and tissue pharmacology of these agents and their metabolites could 
serve as drug effect intermediate endpoints. In addition, retinoic acid receptors could serve as both drug 
and biological effect intermediate endpoints. Possible biological effect surrogate endpoint biomarkers 
include cytomorphological parameters, proliferation markers, genomic markers, regulatory markers, and 
differentiation. Given the demonstrated causality of human papillomavirus (HPV) for cervical cancer, 
establishing the relationship to HPV will be an essential component of any biological intermediate 
endpoint biomarker. The pathologic effect surrogate endpoint biomarker for cervical cancer is CIN, used 
clinically for years. The desired effect for chemopreventive trials is complete regression or prevention 
of progression. In planning chemopreventive trials, investigators need to consider spontaneous regre- 
ssion rates, the subjective nature of detecting CIN, and the impact of biopsy on regression. 
If intermediate endpoint biomarkers that met the above criteria were available for cervical cancer, 
then new chemopreventive agents could be rapidly explored. The efficacy of these new agents could 
be determined with a moderate number of subjects exposed to minimal risk over an acceptable amount 
of time. The impacts on health care for women would be significant. 0 1995 Wiley-Liss, Inc. 
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CLINICAL IMPACT OF CERVICAL CANCER 
Cervix carcinoma is an important and feasible 
target for chemoprevention efforts. This common 
malignancy [I], while not lethal at early stages of 
the disease in most cases, occurs in young, child- 
bearing, sexually active women. Carcinoma is 
thought to result from the progression of cervical 
intraepithelial neoplasia (CIN). 
Cervix carcinoma is an important health prob- 
lem world-wide [l]. In the U.S., 15,800 new cases 
of invasive cervix cancer are predicted in 1995 
with 4,800 deaths attributable to this disease 
(1.8% of all cancer-related deaths in women) C23. 
These figures do not include the more than 
50,000 cases of carcinoma in situ (CIS) and many 
times that number of cases of cervical dysplasia 
for which we have no estimates for incidence or 
prevalence. The age-adjusted death rate for cervi- 
cal carcinoma in the U.S. is 3.2 per 100,000 and 
remains level [3]. Anecdotally, we have observed 
in our clinics an increased number of younger 
women with invasive cervical carcinomas and 
dysplasia. This shift to younger age groups has 
been attributed to the growing spread of human 
papillomavirus (HPV) infections in the popula- 
tion [41. 
A number of important epidemiologic risk 
factors have been identified for developing CW 
and invasive cervical cancer. Early sexual experi- 
ences, the number of sexual partners, and male 
partner factors (number of sexual partners, his- 
tory of venereal disease, early sexual experience) 
are important risk factors L5-81. Smoking in- 
creases the risk of developing cervical cancer [9- 
111. Of key importance is infection with human 
papillomavirus (HPV). HPV DNA sequences can 
be recovered from greater than 90% of cases of 
invasive cervix carcinoma. Whether the links 
between sexual history, smoking, and squamous 
intraepithelial lesions influence risk primarily 
through HPV or whether they are independent 
risk factors suggesting other contributing causes 
of invasive carcinoma remains controversial. 
However, the recent case control trial by Schiff- 
man et al. [12] using PCR assays found that the 
great majority of all grades of CW can be attri- 
buted to HPV infection and that HPV infection 
meets epidemiologic criteria as a causal agent for 
cervical cancer. 
ISSUES FOR CHEMOPREVENTION TRIALS 
Cancer chemoprevention trials pose unique 
problems in design. Chemoprevention agents are 
aimed at a healthy population. Therefore, toxicity 
is intolerable. An effective dose must be deter- 
mined that is not toxic. The dose must be toler- 
ated on a chronic basis over a long period 
(years). Furthermore, in many premalignant con- 
ditions or high-risk individuals, there is no easily 
identifiable therapeutic endpoint. Endpoints for 
cancer clinical trials are usually a measured re- 
duction in tumor size or a statistically measured 
survival in a population whose survival is lim- 
ited. For most chemopreventive interventions, no 
such easily measured endpoints exist. Currently, 
we must rely upon events that happen years 
later, such as the development of cancer. Com- 
plex biostatistical and epidemiologic tools are 
necessary in massive study populations to prove 
clinical efficacy. Another approach is to develop 
new, surrogate endpoint biomarkers. 
Criteria for Surrogate Endpoint Biomarkers 
An optimal intermediate biological endpoint 
for an at-risk population will be readily ex- 
pressed in plasma or in tissues accessible to bi- 
opsy, related in some way to the process of neo- 
plastic transformation, may be easily measured 
from small quantities of tissue, quantifiable as a 
continuous variable, and may be expected to be 
modulated by a chemopreventive intervention. 
The following review describes some of the his- 
tological and molecular changes that occur before 
and/or during the malignant transformation pro- 
cess. Many of these changes are potential surro- 
gate endpoint biomarkers. Our goal is to identify 
the most likely candidates based on the evidence 
available to satisfy the above criteria. 
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BIOCHEMICAL EFFECT SURROGATE 
ENDPOINT BIOMARKERS 
We have defined a biochemical or drug effect 
surrogate endpoint biomarker as an intervention 
which modulates a cell's normal biochemical 
function. Drug effect surrogate endpoint bio- 
markers address three important aspects of a 
chemoprevention trial's design. First, they serve 
as reproducible, quantitative methods for deter- 
mining whether a pharmacodynamically impor- 
tant drug concentration has been delivered intra- 
cellularly to the target site. Second, they can be 
used to define endpoints for Phase I chemopre- 
vention dose searching trials. The use of a drug 
effect surrogate endpoint biomarker as an end- 
point for a Phase I chemoprevention trial recog- 
nizes that the therapeutic index differs for differ- 
ent drug use indications. Third, drug effect sur- 
rogate endpoint biomarkers can be used as mea- 
sures of adequate pharmacodynamic action at 
the target issues in Phase I1 or I11 chemopreven- 
tion trials. Such data can be used as part of an 
adherence assessment. 
An optimal drug effect surrogate endpoint 
biomarker also serves as a biologic surrogate 
endpoint biomarker. Thus, the drug effect sur- 
rogate endpoint biomarker may be a cellular pro- 
duct (protein, carbohydrate, gene expression) of 
a regulatory aspect of cellular growth control or 
a product reflecting changes in a cell that has 
functional but not morphologic transformational 
changes. In many cases, the usefulness of drug 
effect surrogate endpoint biomarkers as biologic 
endpoints is unclear. The drug effect surrogate 
endpoint biomarker becomes one of a number of 
potential biologic surrogate endpoint biomarkers 
that are assessed in Phase IIa and Phase IIb che- 
moprevention trials. 
Potential Surrogates for Retinoid 
Chemoprevention Trials in Cervix 
Drug effect surrogate endpoint biomarkers are 
defined by the drug being tested in a Phase I or 
I1 chemoprevention trial. Retinoids and carote- 
noids have been the primary chemopreventive 
agents tested to date in cervical cancer. Drug 
effect surrogate endpoint biomarkers for these 
agents would represent evidence of effect in 
plasma or at the target site, cervix epithelial cells. 
Fenretinide (CHPR) suppresses retinol in plasma 
(from a normal range of 270-747 ng/ml to 16- 
188 ng/ml). Retinol is easily measured in plasma 
using readily adapted high performance liquid 
chromatography methodology [13]. Cellular ret- 
inol concentration in cervical epithelium has not 
been measured. Extraction procedures from tis- 
sue samples have not been validated, Given the 
accessibility of cervix epithelium, direct measure- 
ment of 4-HPR concentrations in target tissue is 
possible. 
Retinoids are known to exert their biological 
effects by binding to specific nuclear receptor 
proteins, which are members of the steroid re- 
ceptor superfamily. These receptors regulate the 
expression of specific target genes in a ligand- 
dependent manner. Two general classes of these 
receptors have been described, and are known as 
retinoic acid receptors (RARs) and retinoid X 
receptors (RXRs). Phase I chemoprevention Wials 
of new synthetic retinoids (e.g., 9-cis-retinoic acid, 
SR11203, SR11217, TTAB, TTNN) may be based 
upon their specific binding of nuclear RARs or 
RXRs. Thus, drug effect and optimal chemopre- 
ventive doses in the future may be based upon 
specific drug binding to target sites. The poten- 
tial for retinoid regulation of cellular prolifera- 
tion may permit the use of RARs and RXRs as 
biologic as well as drug effect surrogate interme- 
diate biomarkers. 
BIOLOGICAL EFFECT 
SURROGATE ENDPOINT BIOMARKERS 
We define a biological effect surrogate end- 
point biomarker as one in which an intervention 
changes a cellular product. This cellular product 
must be linked to cancer risk, carcinogenic ex- 
posure, carcinogenesis, or tumorigenesis. The 
following are examples of biologic effect surro- 
gate intermediate endpoints for cervical cancer. 
There is compelling molecular and epidemi- 
ological evidence indicating that infection with 
certain genital HPVs has a critical role in the 
cellular changes that precede cervical cancer as 
well as other genital cancers [12,14,151. Of the 
more than 70 characterized HPV types, about 
30% are associated with genital tract infections. 
Whereas 90% of cervical cancers contain HPV 
DNA sequences, only certain genital HPV types 
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are associated with cervical cancer. Lorincz et al. 
[15], in their study of 2,624 women, detected 
HPV DNA in 79.3% of women with confirmed 
cervical neoplasia by Southern blot methods. In 
addition, 23.7% of women with borderline atypia 
and 6.4% of women with a normal cervix were 
positive for HPV DNA. This study defined four 
HPV risk groups based on associations with cer- 
vical cancer. The "low-risk'' group contained 
HPV types 6, 11,42,43 and 44. DNA sequences 
from these virus types were absent from all cer- 
vical cancers but were present in 20.2% of low- 
grade squamous intraepithelial lesions (SIL). An 
"intermediate risk" group consisted of HPV types 
31,33,35,51,52 and 58. Viral DNA was detected 
in 23.8% of high-grade SIL but in only 10.5% of 
cervical cancers. The "high-risk HPV 16" group 
was defined by the presence of HPV 16; DNA 
from this virus type was found in 47.1% of both 
high-grade SIL and cervical cancers. The "high- 
risk HPV 18" group contained HPV 18, 45 and 
56; DNA from these virus types were found in 
26.8% of cervical cancers, but only 6.5% of high- 
grade SIL. 
In most cases of carcinoma, the HPV DNA is 
integrated into cellular genomes, while in CIN 
lesions the viral DNA is extrachromosomal [161. 
Integration appears to be random as far as the 
site of integration in the host chromosome is con- 
cerned. However, the viral genome integrates 
near known oncogenes in some cell lines [173. 
Integration generally occurs in the E l  /E2 region 
of the viral genome, disrupting the E2 viral tran- 
scription regulatory circuit "1. The E2 open 
reading frame (OW) encodes a transcription reg- 
ulatory protein that is a DNA binding protein. 
For HPV 16 and HPV 18, E2 appears to act as a 
repressor of the promoter from which the E6 and 
E7 genes are transcribed [19]. Thus, it is thought 
that disruption of the E2 gene provides a selec- 
tive advantage, leading to uncontrolled prolifera- 
tion of the cell due to deregulated expression of 
E6 and E7 genes [20]. 
In all cell lines examined thus far and in most 
cervical cancers, the E6 and E7 ORFs are pre- 
served and expressed as mRNAs and proteins. 
Continued expression of these proteins is critical 
for maintenance of the malignant phenotype of 
cervical cancer cells [211. In tissue cultures, HPV 
16 and HPV 18 E6 and E7 can profoundly influ- 
ence the growth and differentiation of human 
keratinocytes. Transfection of primary human 
keratinocytes with virus DNA results in immor- 
talization of nontumorigenic cells [22,231. Immor- 
talization is dependent on continued expression 
of E6 and E7 [241. 
Knowing that HPV 16 and HPV 18 E6 bind to 
and promote the degradation of tumor sup- 
presser gene product p53 provides insights into 
the biochemical basis of cell transformation C25, 
261. Furthermore, the E7 product from these vi- 
ruses, the most abundant viral protein in cervical 
cancer cells [27,281, binds to Rb105, another tu- 
mor suppresser gene product [291. The low effi- 
ciency of keratinocyte immortalization by HPV 6 
and HPV 11 is correlated with the weak binding 
of their E6 and E7 gene products to p53 and 
Rb105 [30,311. Expression of E6 may account for 
the accumulation of mutations in immortalized 
cells; p53 is required for G, cell-cycle arrest after 
DNA damage. Kessis et al. [32] have shown that 
E6 expression perturbs G, arrest after DNA dam- 
age, thus permitting DNA replication and fixa- 
tion of mutations. 
The potential biologic effects of surrogate in- 
termediate endpoints related to HPV are the pre- 
sence of viral DNA or the expression of early 
genes E2, E6 or E7. In a model system of normal 
human keratinocytes and several independently 
derived HPV 16 immortalized keratinocyte cell 
lines, Pirisi et al. [331 have recently demonstrated 
that the HPV 16 lines are more sensitive than 
normal keratinocyte cell lines to all-trans-retinoic 
acid. Incubation in all-trans-retinoic acid at 
M caused HPV 16 immortalized keratino- 
cytes to express 2- to 4-fold less viral mRNA 
from E6 and E7 than untreated cells. The cells 
did not terminally differentiate; when the reti- 
noic acid was removed, proliferation resumed. 
Future studies in women with CIN are needed to 
determine if E6 or E7 expression is related to 
progression to invasive disease, or whether sup- 
pression of E6 or E7 expression is related to dis- 
ease regression. The other criteria for surrogate 
endpoint biomarkers have been met. 
Cytomorphometry 
The cellular morphology used to identify SIL 
could serve as a surrogate endpoint biomarker. 
Nuclear and cytological parameters such as size, 
density, nuclear/cytoplasm ratio, texture and 
geometry of nuclei have been examined to im- 
prove the diagnosis of cervical cancer [34-391 
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and other diseases. However, the issue in chemo- 
prevention of cervical cancer is not only diagno- 
sis, but prediction of progression or regression of 
preinvasive disease states. 
Few studies collect data that can address this 
issue. Rosenthal et af. [341 found that nuclear 
mean optical density, cytoplasm mean optical 
density, and nuclear-cytoplasm area ratio, along 
with autocorrelations of nuclear optical density, 
were predictive of progression or regression in 
23 cervical smears; 7 progressed and 16 regres- 
sed without any intervention. Kwikkel ef aE. [35] 
found no features predictive of progression ver- 
sus nonprogression in one set of women (n = 41). 
In another set of women (n = 20), they found cell 
area, shape of nucleus, and mean density of nu- 
cleus to correctly classify 80% of the specimens 
as progression or nonprogression [35]. A unique 
aspect of this study was the emphasis on visu- 
ally normal intermediate cells rather than visu- 
ally abnormal cells as the basis for prediction 
[351. Thus, the available data on cytometric fea- 
tures that predict progression or regression are 
based on a small number of women and have 
inconsistent findings. 
It remains unclear whether cellular or nuclear 
morphology will be useful surrogate endpoint 
biomarkers for cervical cancer. In contrast, some 
form of quantitative cytology and histopathology 
will be essential to assure accurate identification 
and classification of patients in chemoprevention 
trials. 
Genomic Markers 
The chromosomal karyotyping of cervical le- 
sions has shown that the lesions can be diploid 
or euploid, polyploid or aneuploid. Some au- 
thors believe ploidy is a good predictor of bio- 
logical behavior of cervical cancer [40], but the 
available data are conflicting and inconsistent. In 
addition, most studies have been done in women 
with invasive cervical cancer, which is not the 
target for chemoprevention. Any findings from 
these studies are likely not relevant to earlier 
stages of disease. 
Studies among women with earlier stages of 
disease have some interesting but still inconsis- 
tent findings about DNA content or ploidy sta- 
tus. There appears to be a trend of higher per- 
centages of women with aneuploidy with severe 
dysplasia or CIS compared to CIN I or I1 [41461. 
However, others have demonstrated no differ- 
ence in ploidy status between normal cervical 
tissue and abnormal [471 and 100% aneuploid 
status in CIN I [48]. The issue of progression 
versus regression has been associated with 
ploidy status in two studies [41,491. HPV has 
been shown to alter the determination of DNA 
content or ploidy findings [42,46,48,501 suffici- 
ently that HPV should always be measured. 
Most of the studies noted above failed to deter- 
mine the presence of HPV infection. Future 
studies of genomic markers need larger sample 
sizes of preinvasive disease states and consistent 
assays of ploidy along with quantitative histo- 
pathology and determination of HPV status and 
viral type before consideration as a surrogate 
endpoint biomarker. 
Measures of genomic instability may be useful 
surrogate endpoint biomarkers. The available 
data is minimal. Kaelbling and colleagues [51] 
demonstrated loss of heterozygosity of chromo- 
some region 1 7 ~ 1 3  in HPV-negative tumors. 
Other studies revealed nonrandom structural 
changes in chromosomes 1, 3, 11, and 17p, with 
specific allelic losses on 3p reported in up to 
80-90% of tumors, and 30% on l lq [52]. In con- 
trast, Rader and colleagues [521 did not detect 
loss of heterozygosity in any of 15 early stage 
cervical cancers, all positive for HPV. As with 
other genomic markers, a great deal more work 
needs to be done before considering genomic 
instability as a surrogate endpoint biomarker. 
Proliferation Markers 
The carcinogenic transformation of normal 
cells to cancer is clearly linked to significant 
changes in cellular kinetics. Proliferation markers 
and corresponding indices, such as mitotic index, 
S-phase fraction, Ki-67, etc., have been used to 
describe the cellular kinetics of normal cells, dys- 
plastic cells, and cancerous cells. Brugal [53] has 
argued that three types of markers are necessary 
to describe malignant population growth kin- 
etics: one measures the growth fraction (e.g., Ki- 
67), a second evaluates cell cycle speed in arbi- 
trary units, and a third assesses the S-phase cell 
occurrence frequency (e.g., BrdU and PCNA). All 
of these markers of cellular kinetics have the 
potential to serve as surrogate endpoint bio- 
markers. 
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The monoclonal antibody Ki-67 binds to a 
nuclear antigen expressed by cycling cells of 
several human tissues and to the cytoplasm of 
basal layer cells in squamous epithelia. Among 
women with invasive squamous cell carcinoma 
of the cervix, a range of 10-50% Ki-67 staining 
has been observed, indicating considerable vari- 
ation in tumor growth rates 1541. In addition, 
there was no significant relationship between 
Ki-67 staining and conventional histological par- 
ameters [541, but a high Ki-67 score has been 
associated with early recurrence [55]. Rishi and 
colleagues [561 have used Ki-67 on 40 benign and 
malignant tumors, using cytological smears and 
frozen tissues. The number of Ki-67 positive cells 
on cytological smears correlated well with Ki-67- 
cells from corresponding tissue. These studies 
suggest that Ki-67 could be used on cytological 
smears from the cervix instead of using biopsy 
specimens. If the other criteria for surrogate end- 
point biomarkers are established for Ki-67, then 
this collection approach would be quite useful, 
With the availability of a monoclonal antibody 
to bromodeoxyuridine (BrdU), BrdU-containing 
nuclei can be identified. Very few studies have 
evaluated the use of BrdU in cervical tissue. 
Fukuda et al. [571 found that BrdU-positive cells 
were mainly located in the parabasal area of 
normal epithelia and distributed throughout the 
epithelium with severe dysplasia and CIS. How- 
ever, marked intra-tumor heterogeneity has been 
demonstrated [581 and the delivery method re- 
quires involved intravenous administration or in- 
tracervical injections [57]. Thus BrdU does not 
currently look very feasible as a surrogate end- 
point biomarker. 
Proliferating cell nuclear antigen (PCNA, 
cyclin), first detected in 1978, has been suggested 
to be necessary for DNA replication and cellular 
proliferation. The pattern of PCNA staining in 
normal cervical epithelium is localized to the 
parabasal area. Several studies of PCNA have 
demonstrated increased activity from normal epi- 
thelia to condyloma with and without dysplasia 
to moderate and severe dysplasia, showing in- 
creasing disruption of normal regulation of cell 
proliferation [59,601. In addition, the loss of neg- 
ative growth control demonstrated by changes in 
PCNA appears to be linked to consequences of 
HPV infection, through either loss of p53 func- 
tion 1601 or epidermal growth factor receptor 
(EGFR) regulatory mechanisms 1611. PCNA has 
good supporting data and is feasible to collect 
and measure, therefore, it is a strong candidate 
for use as a surrogate endpoint biomarker. 
It remains unclear whether one proliferative 
index is enough to describe the cellular kinetics 
of a neoplasm. Given the available data, we rec- 
ommend incorporation of both Ki-67 and PCNA 
as possible surrogate endpoint biomarkers. 
Regulatory Markers 
The transformation of a normal cell into a can- 
cer cell is a complex multistep process resulting 
in a clone of cells that are no longer under nor- 
mal regulatory control. Advances in several 
fields have provided several regulatory markers 
to investigate the different steps in carcinogene- 
sis related to regulatory control. The potential 
regulatory markers include transcription factors, 
oncogenes, and tumor suppresser genes. 
Studies in oncogenes and cervical carcinoma 
have been done primarily in women with inva- 
sive disease. The expression of c-myc oncogene 
has been reported to increase from normal tissue 
to invasive disease [62-661, but the correlation 
with prognosis or relapse is inconsistent 165-701. 
Other potential oncogenes include Ha-ras which 
is expressed primarily in high-grade or invasive 
lesions [66,67]. In evaluating each of these onco- 
genes as a potential surrogate endpoint bio- 
marker, the impact of HPV needs to be consid- 
ered. HPV appears to have significantly more 
impact on disease state and progression than 
overexpression of any oncogene in the studies 
that have measured both HPV and other onco- 
genes [69,71-741. 
The expression rate of EGFR correlates with 
growth properties in a squamous carcinoma cell 
line. The presumption is that EGFR could be a 
useful surrogate endpoint biomarker for cervical 
cancer. EGFR expression has been noted in inter- 
mediate and superficial areas in severely dys- 
plastic lesions and primarily in basal regions in 
normal epithelium [75,761. Various clones of the 
C4-I cervical cancer cell line demonstrated no 
correlation between growth rate, expression of 
EGFR, and level of HPV gene products [77]. 
Among 97 HPV lesions of the cervix, EGFR and 
c-ubB-2 were not associated with specific HPV 
types, grade of CIN, or the clinical course [78]. 
Thus, the available data does not strongly sup- 
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port the potential of EGFR as a surrogate end- 
point biomarker for cervical cancer. 
Differentiation Markers 
Cervical epithelium differentiates along the 
squamous pathway in carcinogenesis. Thus, 
markers related to this pathway could be surro- 
gate endpoint biomarkers. Several different po- 
tential surrogate endpoint biomarkers related to 
differentiation include keratins and involucrin. 
Intermediate filaments, characterized by keratins, 
are a major cytoskeletal element present in vir- 
tually all epithelial cells. Keratins represent many 
different polypetides ranging in molecular 
weight from 40-70 kD. They can be further sub- 
divided into two groups according to molecular 
weight and electrophoretic mobility. At least one 
keratin from each of these two subgroups is 
present in all epithelial cells. The ectocervical 
epithelium contains type I1 keratins 1,4,5 and 6, 
and type I keratins 13,14, 15, and 19 with some 
variable expression of keratins 2, 8, 10, 11, 16, 
and 17 [79]. There is evidence to suggest that 
changes take place in the keratin polypeptide 
distribution from normal cervical epithelium to 
CIN and cervical cancer [8OJ. This requires the 
use of several monoclonal antibodies to detect 
the differences. Earlier studies, which relied 
upon a few monoclonal antibodies such as 
CAM 5.2, may have limited ability to detect 
changes in the various heterogeneous groups. 
Keratins may serve as a surrogate endpoint bio- 
marker if the specific phenotype related to CIN 
and progression to invasive disease could be 
delineated. 
Involucrin is a cytoplasmic protein synthe- 
sized in stratified squamous epithelia. It is the 
major precursor to the crosslinked envelope 
formed immediately beneath the cellular plasma 
membrane of maturing squamous epithelial cells. 
Involucrin is absent from the basal and sugra- 
basal cell layers and only detected at the outer 
portion of the epithelium where it becomes 
crosslinked. Therefore, involucrin could serve as 
a specific marker of normal squamous differen- 
tiation and maturation. Involucrin expression is 
altered in preneoplastic and neoplastic conditions 
of numerous squamous epithelia, including the 
cervix. With respect to cervix, involucrin can be 
considered a highly specific marker of squamous 
cell differentiation in both normal and patho- 
logical epithelium 181,821. The orderly staining 
pattern restricted to the outer layers of normal 
squamous cervical epithelium is generally lost in 
preinvasive and invasive cervical lesions. How- 
ever, there is a vast spectrum of staining patterns 
from normal epithelium to malignant lesions. 
Recent studies suggest that involucrin appears 
unable to reliably differentiate between benign 
and neoplastic conditions [83,84]. Inconsistency 
among available data could be improved if the 
technique for interpreting staining patterns could 
be refined to a more objectively consistent pro- 
cess, such as computerized interpretatiodim- 
aging. Involucrin is a potential surrogate end- 
point biomarker since it can be done on biopsy 
specimens, but the technical issues need to be 
addressed and the relationship to neoplastic dis- 
ease needs to be clarified. 
PATHOLOGICAL EFFECT 
SURROGATE ENDPOINT BIOMARKERS 
We define a pathologic effect surrogate end- 
point biomarker as one in which a defined lesion 
such as CIN or low-grade/high-grade SIL re- 
verses after a defined treatment period. This 
pathologic endpoint permits the use of a "gold 
standard" proof of surrogate biomarker efficacy 
and makes CIN an attractive human model to 
identify surrogate endpoint biomarkers in cancer 
chemoprevention [85]. 
Squamous Cell Carcinoma 
as a Continuum of CIN 
Squamous cell carcinoma usually arises from 
the squamous-columnar junction of the cervix, 
and is preceded by, and thought to result from, 
the progression of cervical dysplasia and CIS 
[86,87]. Further support for a continuum of dis- 
ease is provided by the observation that cervical 
dysplasia is most often diagnosed among women 
in their 20s, CIS in their 30s, and invasive cancer 
after the age of 40 [%I. 
Recent information challenges the assertion 
that invasive carcinoma of the cervix is part of a 
continuum from CIN. The alternative view is 
that CIN I and CIN 11-111 are distinct disease 
processes with CIN I being the consequence of a 
self-limited, sexually transmitted viral infection 
and CIN 11-111 being a cervical cancer precursor 
lesion [891. Several observations support this as- 
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sertion. First, the anatomic distribution of CIN I 
is different (peripheral cervical lesions) from CIN 
11-111 (central cervical lesions) [90]. Second, the 
mean age of women with CIN I and CIN 11-111 
are comparable in incident case analysis [SI as 
distinguished from prevalent case analyses [911. 
Thus, the concept that younger women with CIN 
I progress to higher grades of CIN may be erron- 
eous. Third, 61% of women with CIN 11-111 never 
had a smear showing CIN I [92]. Fourth, 50-90% 
of CIN lesions most likely to regress are caused 
by HPV types other than "high-risk", whereas 
lesions most likely to progress to invasive carci- 
noma are caused by high-risk HPV types [121. 
Finally, in vitro infection of human keratinocytes 
with HPV 16 produces a stratified epithelium 
that resembles CIN 11-111; infection with HPV 6 
results in a stratification resembling CIN I [931. 
A substantial proportion of CIN spontane- 
ously regresses [94]; CIN I regress more fre- 
quently than CIN I1 or 111. The relative frequency 
of spontaneous regression varies widely from 
11% to 44% [95-971 among published reports of 
this phenomenon. Biopsies of the suspected 
small lesions have either cured the dysplasia or 
have stimulated an inflammatory response about 
the biopsy that destroys the residual CIN [983. 
Spontaneous regression of CIN I11 is rare [98]. 
Use of CIN as the Pathological Effect 
Surrogate Endpoint Biomarker 
Using CIN or SIL as an endpoint for studies is 
difficult because of high spontaneous regression 
rates. However, the clinical significance of treat- 
ing a disease that is likely to regress spontane- 
ously is in doubt. Therefore, some have limited 
their chemopreventive studies to CIN II and 111 
or high-grade SIL. Historically, the follow-up of 
pregnant women with CIN I11 involves an initial 
assessment with colposcopy and biopsy and cy- 
tological follow-up. Treatment is delayed until 
after delivery as long as the colposcopy is ade- 
quate and the lesion and cytology do not change 
during pregnancy. Therefore, chemoprevention 
studies using CIN 111 are possible and have been 
done without risk to women as long as all sub- 
jects receive close observation and follow-up. 
This reduces the problem with spontaneous re- 
gression and reduces the number of women re- 
quired. The compromise is that CIN 111 may rep- 
resent a lesion that is too late for chemopreven- 
tive intervention. In addition, far more women 
suffer from the diagnosis of CIN I or CIN 11, so 
the impact in the U.S. will be less. 
SUMMARY 
The list of potential surrogate endpoint bio- 
markers for cervical cancer can be overwhelm- 
ing. In this review, we have highlighted available 
data for more commonly noted candidates. We 
believe that our model of evaluating potential 
chemopreventive agents based on biochemical 
effect, biological effect and pathological effect 
allows for a focused, systematic investigation. 
Clearly, the most critical issue is selecting valid 
surrogate endpoint biomarkers. Currently, we 
are focusing our efforts on retinoid-related che- 
mopreventive agents for CIN, so we have chosen 
plasma levels and tissue levels of retinoids as a 
biochemical effect. The RAR and RXR were cho- 
sen for both biochemical and biological effects. 
The other biologic effect surrogate endpoints are 
E6 and E7 expression of HPV , along with PCNA 
and Ki-67. Finally, we include the pathological 
effect of regression, progression or no change of 
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